FLAME: Airway Inflammation Monitoring in Asthma and Cystic Fibrosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00404859|
Recruitment Status : Completed
First Posted : November 29, 2006
Last Update Posted : December 4, 2006
Background By means of measurements of series of non-invasive inflammatory markers in exhaled breath (condensate), a reflection of inflammatory processes and oxidative stress, can be obtained. Thereby, these techniques could be important in monitoring asthma and CF lung disease in children. Fractional exhaled nitric oxide (FeNO) and inflammatory markers in exhaled breath condensate (EBC) reflect ongoing inflammation and oxidative stress in the airways. These markers have a promising capacity for monitoring diagnoses of CF and asthma lung disease.
Aim To study the course of inflammatory markers in time in children with asthma and CF, in stable periods and during pulmonary exacerbations. In addition, we study the ability of inflammatory markers to predict safe tapering of medical treatment in both populations.
- To study the course of inflammatory markers in EBC during an exacerbation.
- To study which IM are already elevated before a clinical exacerbation is evident and can predict exacerbations in time.
- To study which inflammatory markers can predict safe discontinuation of antibiotics in children with CF, or tapering of inhaled corticosteroids in children with asthma.
- To study the relationship between inflammatory markers in EBC, the severity and control of CF and asthma, the symptoms and lung function within patients will be analysed.
Methods Children with CF (n=30) and children with asthma (n=40) were recruited included from our outpatient clinic. During this longitudinal study patients visit the outpatient clinic were followed–up for 12 months; every two months during one year. patients visited our outpatient clinic. In addition to these standard visits, During exacerbations patients four extra visits were planned during an exacerbation. were asked to visit the University Hospital Maastricht four times. These additional visits were planned with a maximum of two times during the study. By means of a home monitor, children were asked to assess measurements of Besides measurements in the University Hospital, children measured forced expiratory volume in one second (FEV1) at home using a home monitor, to record medication use, and, to record presence and severity of pulmonary symptoms. Outcome parameters were: 1) FeNO assessment in exhaled air, 2) inflammatory markers in EBC, 3) lung function parameters, 4) specific questionnaires to assess asthma and CF control and severity, 5) data originating from the home monitor.
|Condition or disease|
|Asthma Cystic Fibrosis|
|Study Type :||Observational|
|Enrollment :||70 participants|
|Official Title:||Monitoring Chronic Airway Inflammation in Children With Asthma and Cystic Fibrosis|
|Study Start Date :||January 2006|
|Study Completion Date :||June 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00404859
|University Hospital Maastricht|
|Maastricht, Netherlands, 6202AZ|
|St Radboud Childrens Hospital|
|Máxima Medical Centre|
|Principal Investigator:||Charlotte M Robroeks, MD||Maastricht University Medical Center|
|Study Director:||Edward Dompeling, MD, PhD||Maastricht University Medical Center|
|Study Director:||Quirijn Jöbsis, MD, PhD||Maastricht University Medical Center|